Vertex Nabs ENaC Inhibitors | Chemical & Engineering News
Volume 93 Issue 24 | p. 17 | Concentrates
Issue Date: June 15, 2015

Vertex Nabs ENaC Inhibitors

Department: Business
Keywords: pharmaceuticals, biotech, cystic fibrosis, rare diseases

Vertex Pharmaceuticals will pay Parion Sciences $80 million for access to epithelial sodium channel (ENaC) inhibitors for the treatment of cystic fibrosis. The deal includes P-1037, which is currently in a Phase II study. Vertex and Parion are also planning a study combining P-1037 with Vertex’s CF treatments lumacaftor and ivacaftor in people with two copies of the F508del mutation, the most common mutation driving the disease. Vertex says it will also explore the ENaC inhibitors as treatments for other pulmonary diseases.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment